



## Correction: Nd:YAG/Er:YAG dual laser vs. topical steroid to treat vulvar lichen sclerosus: study protocol of a randomized controlled trial

Volker Viereck<sup>1</sup> · Marianne Gamper<sup>1</sup> · Sigrid Regauer<sup>2</sup> · Claudia Walser<sup>1</sup> · Irena Zivanovic<sup>1</sup>

Published online: 24 October 2023

© Springer-Verlag GmbH Germany, part of Springer Nature 2023

**Correction: Archives of Gynecology and Obstetrics**  
**(2023) 308:643–649**  
<https://doi.org/10.1007/s00404-023-07055-z>

Table 1 of this article was mistakenly published with incorrect data. The correct Table 1 is provided below.  
The original article is also updated.

---

The original article can be found online at <https://doi.org/10.1007/s00404-023-07055-z>.

---

✉ Volker Viereck  
volker.viereck@stgag.ch

<sup>1</sup> Department of Gynecology and Obstetrics, Cantonal Hospital Frauenfeld Postfach, 8501, Frauenfeld, Switzerland

<sup>2</sup> Institute of Pathology, Medical University Graz, Graz, Austria

**Table 1** Study plan, treatment of LS, RCT laser vs. steroid

TIMEPOINT	Enrollment	Post-allocation						Follow-ups		
	Screening - 1 M <sup>a</sup>	Baseline 0 M	1 M <sup>b</sup>	2 M	(3 M) <sup>c</sup>	4 M	(5 M) <sup>c</sup>	6 M	12 M	24 M <sup>d</sup>
VISITS:	X	X	(X)	X		X		X	X	X
ENROLLMENT:										
Eligibility screen:	X									
Demographics, medical history	X									
Inclusion / exclusion criteria	X									
Informed consent	X									
Allocation		X								
INTERVENTIONS:										
Laser treatment:		X	X	X		X				
VAS pain during/after laser treatment		X	X	X		X				
Steroid treatment <sup>e</sup> :		←————→			←-----→		←-----→			
Hand out steroid medication and treatment scheme		X		X		X				
ASSESSMENTS:										
Clinical examination, photo documentation and sketch	X	X	(X)	X		X		X	X	
Clinical LS score	X	X	(X)	X		X		X	X	
VSQ	X	X	(X)	X		X		X	X	X
VAS symptom strength	X	X	(X)	X		X		X	X	X
Adverse events		X	(X)	X		X		X	X	X
PGI-I								X	X	X
Therapy log		X	(X)	X		X		X	X	X
Treatment history									X	X
Telephone interview										X
Vulvar biopsy	X							X		

M month, VAS visual analog scale (0–10), LS lichen sclerosus, VSQ Vulvovaginal Symptoms Questionnaire, PGI-I Patient Global Impression of Improvement

<sup>a</sup>Any concomitant steroid treatment has to be stopped  $\geq 2$  weeks before

<sup>b</sup>1 M visit and assessment only for laser group (X)

<sup>c</sup>No visits at (3 M) and (5 M)

<sup>d</sup>Telephone visit

<sup>e</sup>Steroid dose: high (months 1 and 2), medium (months 3 and 4), low (months 5 and 6)

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.